The efficacy and safety of Certolizumab Pegol over 52 weeks was compared in two groups of patients: Group 1 comprised patients naïve to biologic treatments; Group 2 comprised patients previously treated with one or more anti-Tumor necrosis factor (TNF)-alpha and/or antiinterleukin (IL) agents.
Dattola, A., Vollono, L., Cannizzaro, M.v., Caposiena Caro, R.d., Mazzilli, S., Melino, G., et al. (2021). Efficacy of certolizumab pegol in naïve versus multi-treated patients affected by psoriatic arthritis. ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 156(4), 434-439 [10.23736/S0392-0488.20.06623-7].
Efficacy of certolizumab pegol in naïve versus multi-treated patients affected by psoriatic arthritis
Melino, Gennaro;Candi, Eleonora;Campione, Elena;Bianchi, Luca
2021-01-01
Abstract
The efficacy and safety of Certolizumab Pegol over 52 weeks was compared in two groups of patients: Group 1 comprised patients naïve to biologic treatments; Group 2 comprised patients previously treated with one or more anti-Tumor necrosis factor (TNF)-alpha and/or antiinterleukin (IL) agents.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Efficacy of Certolizumab Pegol in naïve versus multi-treated.pdf
solo utenti autorizzati
Tipologia:
Versione Editoriale (PDF)
Licenza:
Copyright dell'editore
Dimensione
695.07 kB
Formato
Adobe PDF
|
695.07 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
